

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Occupational cancer risk surveillance in HIV-infected individuals exposed to chemicals: Role of p53 molecular marker

Donald C. Udah^{1,6}, Adeleye S. Bakarey^{2,7}, Gloria O. Anetor³, Maxwell Omabe⁴, Victory F. Edem⁵, Olusegun G. Ademowo^{2,8}, John I. Anetor^{1*}

¹Laboratory for Toxicology and Micronutrient Metabolism, Department of Chemical Pathology, College of Medicine, University of Ibadan, Ibadan, Nigeria.

²Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Nigeria.

³Department of Public Health Science, Faculty of Health Sciences, National Open University of Nigeria (NOUN), Abuja, Nigeria.

⁴Department of Medical Laboratory Sciences, School of Biomedical Science, Faculty of Health Science, Ebonyi State University, Nigeria.

⁵Department of Immunology, University of Ibadan, Ibadan, Nigeria.

⁶JSI Research & Training Institute Inc. (JSI), Abuja, Nigeria

⁷Department of Biomedical Laboratory Science, College of Medicine, University of Ibadan, Ibadan, Nigeria.

⁸Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Ibadan, Nigeria

*Corresponding author
johnanetor@gmail.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 **Abstract**

28 The growing exposure to occupational chemicals and HIV infection are both major global
29 health issues. However, there is little data on the carcinogenic risk profile of HIV-infected
30 individuals who have been occupationally exposed to chemical mixtures. This study therefore
31 investigated the levels of cancer risk biomarkers in HIV-infected individuals exposed to
32 occupational chemicals, exploring the relationship between apoptotic regulatory markers and
33 DNA oxidative response markers as a measure of cancer risk.

34 Apparently healthy adults (mean age 38.35 ± 0.72 years) were divided into four groups according
35 to their HIV status and occupational chemical exposure: 62 HIV positive exposed (HPE), 66
36 HIV positive unexposed (HPU), 60 HIV negative exposed (HNE), and 60 HIV negative
37 unexposed (HNU). Serum p53, bcl2, 8-hydroxydeoxyguanosine (8-OHdG), superoxide
38 dismutase (SOD), and malondialdehyde (MDA) were estimated by standard methods. Blood
39 samples were analysed for CD4 cell count by flow cytometry.

40 Serum p53 and bcl2 levels in HPE (0.91 ± 0.11 ng/ml and 122.37 ± 15.77 ng/ml) were
41 significantly lower than HNU (1.49 ± 0.15 ng/ml and 225.52 ± 33.67 ng/ml) ($p < 0.05$),
42 respectively. Wildtype p53 and bcl2 were positively and significantly correlated with 8-OHdG
43 ($r=0.35$, $p<0.001$; $r=0.36$, $p<0.001$) and SOD ($r=0.38$, $p<0.001$; $r=0.39$, $p<0.001$). After
44 controlling for gender, age, BMI, and cigarette smoking, both HIV status and SOD activity
45 were significantly associated with wildtype p53 and bcl2 ($p < 0.05$). Malondialdehyde was
46 significantly higher in the HPE (0.72 ± 0.01 mg/ml) than in the HNE (0.68 ± 0.01 mg/ml) and
47 HNU (0.67 ± 0.01 mg/ml) groups ($p < 0.05$). Additionally, the HPE group (578.87 ± 33.64
48 cells/ μ L) exhibited significantly lower CD4 counts than the HNE (785.35 ± 36.8 cells/ μ L) and
49 HNU (862.15 ± 43.29 cells/ μ L) groups. Individuals infected with HIV and occupationally
50 exposed to chemical substances exhibit compromised immunity, elevated oxidative stress, and
51 depressed p53 (loss of tumour suppressive capacity) and bcl2; a convergence promoting the
52 carcinogenic pathway and elevated cancer risk. These findings provide a mechanistic basis of
53 cancer risk and scientific justification for preventive strategies against carcinogenesis in
54 individuals who are HIV-infected.

55
56 **Keywords:** Cancer risk, HIV, Occupational exposure, Oxidative stress, p53

57

58 **Introduction**

59 Epidemiological studies have demonstrated that patients with compromised immune systems,
60 such as those seen with HIV infections, have a higher cancer incidence rate [1–3]. In addition,
61 patients with AIDS-defining cancers had a poor prognosis prior to the introduction of Highly
62 Active Antiretroviral Therapy (HAART), with a median survival of 5 to 6 months [4]. The
63 increased availability of HAART has largely contributed to the reduction in the risk of AIDS-
64 defining cancers, allowing HIV-infected individuals to live longer [5]. This has resulted to
65 reduced incidence of malignancies linked to AIDS and weakened immunity, such as Kaposi
66 sarcoma and non-Hodgkin's lymphoma [6]. However, the occurrence of non-AIDS defining
67 malignancies is increasing among people infected with HIV [7].

68 Although the mechanisms underlying the increased risk of cancer among HIV-infected
69 individuals remain poorly understood, it may be associated with non-HIV factors such as
70 occupational exposure to toxic metals. Thus, HIV infection and occupational exposure to

71 hazardous chemicals are two risk factors that may be associated with the disruption of
72 immunological and/or non-immune surveillance systems against cancer, especially the p53
73 dependent metabolic cascade. The tumour suppressor p53 and the anti-apoptotic protein bcl2
74 were two of the first cancer genes identified, and their interaction is critical for cancer biology
75 [8].

76 Many people, including those living with HIV, work in a variety of occupations. Some of these
77 jobs are well-known to expose workers to toxic metals like lead, mercury, chromium, and
78 cadmium, volatile organic compounds (VOCs) like benzene particularly from sources like
79 motor-vehicle exhaust and gasoline-vapor emissions, and skin-irritating substances including
80 oils, greases, solvents, and detergent [9–12]. Exposure to chemical mixtures, including toxic
81 metals, is a common risk factor for cancer, especially among certain occupational groups,
82 because various substances prevalent in industrial and agricultural environments have been
83 identified as carcinogenic [13–17]. These chemicals can cause DNA damage, resulting in
84 mutations and abnormal cellular behaviour. Additionally, genetic and epigenetic alterations are
85 known to predispose a cell clone to malignancy [18]. Multiple defence mechanisms, both
86 immunological and non-immune surveillance system, may be employed to ward off this threat
87 [19]. The best-known form of genetic surveillance against cancer acts through the p53-
88 dependent pathway, with the p53 tumour suppressor gene dubbed the "Guardian of the
89 Genome" [20]. It prevents genomic instability and suppresses tumourigenesis through
90 regulation of diverse cellular processes including cell proliferation, DNA repair, and cell death
91 [21].

92 The wildtype p53 protein binds to DNA, specifically the promoter region of p21, which is a
93 cyclin-dependent kinase inhibitor, halting the cell cycle in the G1 phase. [22]. This cell cycle
94 arrest allows time for cells to repair DNA damage caused by cytotoxic stressors [23].
95 According to Leroy *et al.* [24], more than 50% of all human tumours carry p53 mutations.
96 These mutations impair the DNA-binding capacity of the p53 protein. Consequently, cells with
97 damaged DNA but with maintained mitotic capacity go on dividing and increasing the risk of
98 cancer. However, there is a paucity of studies that evaluate the p53 protein in HIV patients who
99 are occupationally exposed to chemical mixtures. The present study aimed to evaluate whether
100 levels of apoptotic regulatory markers p53 and bcl2 are associated with HIV infection,
101 occupational exposure, oxidative damage, and antioxidant protection.

102

103 **Materials and Methods**

104 **Study population**

105 This was a cross-sectional study conducted in Nigeria involving 128 HIV positive and 120 HIV
106 negative consenting adults, with a mean age of 38.35 ± 0.72 years. Apparently healthy HIV-
107 positive and HIV-negative adults were recruited from both the community and a health facility
108 between April 2017 and October 2017. Individuals who tested HIV negative in the community
109 and those who visited the HIV Testing and Counselling units at the health facility for a
110 voluntary HIV testing service and tested negative were matched for age, sex, and similarity in
111 environmental as well as occupational characteristics with HIV positive cases, all recruited into
112 the study.

113 A structured questionnaire was administered to elicit relevant information, including
114 occupational exposure data. Thus, based on HIV status and occupational chemical exposure,

115 the study population (N = 248) was divided into 4 groups: HIV positive exposed (HPE; n =
116 62), HIV positive unexposed (HPU; n = 66), HIV negative exposed (HNE; n = 60), and HIV
117 negative unexposed (HNU; n = 60). The study specifically examined two distinct groups:
118 individuals who were occupationally exposed to chemicals and an unexposed category. The
119 occupationally exposed cohort, consistent with previous studies, had worked in professions
120 associated with toxic metals and hazardous chemicals. These occupations included Cement
121 factory worker [25,26], Electrician [27,28], Bars & Night clubs worker [29,30], Mechanic
122 [9,31], Painter & Printing press worker [9,10], Weed sprayer & Pesticides worker [11,32,33],
123 Welder [12], and Petrol Station Dispenser [34]. Furthermore, the unexposed category includes
124 those who work in vocations that are considered low risk for toxic metal exposure, such as
125 teachers, students, and administrative personnel in both the commercial and public sectors (data
126 entry clerks, customer service clerks, receptionists).

127 The exclusion criteria for participation in the project were any history of hereditary immune
128 deficiency, primary immune deficiency, autoimmune disease, or immunosuppressive drug use;
129 previous cancer diagnosis; supplement use at the time of the study or within the month
130 preceding it; prospective participants' refusal to consent or inability to give consent to
131 participate in this study; age <18 years. Participants were consecutively identified and recruited
132 into the study. The HIV status of participants in this study was confirmed using the national
133 HIV testing algorithm [35].

134 **Ethics statement**

135 The study was approved by the Ethics Committee of the University of Ibadan/University
136 College Hospital (UI/EC/16/0226) after a review process. Additionally, a written formal
137 informed consent was obtained from all the participants selected.

138 **Anthropometric measurements**

139 Body weight (kg) was measured using an electronic scale with an accuracy of 0.1 kg, and height
140 was measured using a stadiometer with an accuracy of 0.1 cm. Each participant's body mass
141 index (BMI) was calculated as weight in kilograms divided by the square of the height in meters
142 (kg/m^2).

143 **Sample collection**

144 Blood samples were aseptically obtained from each participant using disposable, pyrogen-free,
145 vacutainer needles. Whole blood (5ml) was collected into serum separator tubes (SST) and
146 2mls into k3-EDTA vacutainers. Samples collected into SST were allowed to clot in an upright
147 position for at least 30 minutes but not longer than 1 hour before centrifugation at 2200-2500-
148 RPM for 15 minutes. The serum was aliquoted into cryogenic vials while other samples not
149 immediately required were stored at -86°C until ready for analysis.

150 **Quantification of CD4+ lymphocytes**

151 The identification and the enumeration of CD4+ T lymphocytes were determined using the
152 Becton Dickinson (BD) FASCount system (Becton, Dickinson and Company, California,
153 USA); a flow cytometry method that uses a specific monoclonal antibody and fluorescence-
154 activated cell-sorter (FACS) analysis [36]. Samples were analyzed within 6 hours of collection.
155 The Centers for Disease Control and Prevention (CDC) classification system of HIV-infected
156 individuals were used to further categorize the study population into three groups: CD4 counts
157 (a) ≥ 500 cells/ μL ; (b) 200-499 cells/ μL and (c) <200 cells/ μL [37].

158 **Determination p53, bcl2, SOD and 8OHdG**

159 The serum levels of p53, bcl2, SOD and 8OHdG were determined using the ELISA method in
160 accordance with the manufacturer's procedure (Melsin Medical Co., Limited, China). These
161 kits are based on the principle of a one-step double-antibody sandwich enzyme-linked
162 immunosorbent assay (Voller *et al.*, 1978). In this approach, standard or test sample or control
163 specimen and monoclonal antibodies specific for the analyte of interest conjugated to
164 Horseradish Peroxidase (HRP-Conjugate) were introduced to polystyrene microwell strips pre-
165 coated with monoclonal antibodies specific for the analyte of interest (p53 or bcl2 or SOD or
166 8OHdG). Chromogen solutions were added after incubation and washing, and the reaction
167 stopped within a pre-specified time. The ELx808 Absorbance Microplate Reader (BioTek
168 Instruments Inc., Winooski, Vermont USA) was used to determine the optical density at 450
169 nm. The concentrations of analytes of interest in the samples were then extrapolated from
170 standard curves using the optical density of each sample. Internal quality control was
171 performed by analysing external reference samples together with the test samples. Human p53
172 ELISA kit (Catalogue No: EKHU-0309), Human bcl2 ELISA kit (Catalogue No: EKHU-
173 0302), Human SOD ELISA kit (Catalogue No: EKHU-1058), and Human 8OHdG ELISA kit
174 (Catalogue No: EKHU-1276) acquired from Melsin Medical Co., Limited, China were of the
175 highest commercially analytical grade and had an intra-assay CV (%) < 10% and Inter-assay
176 CV (%) < 15%.

177 **Measurement of serum MDA levels**

178 The Malondialdehyde (MDA) colorimetric assay previously described by Buege & Aust [38]
179 was used. In this method, the free MDA present in the sample which was a product of lipid
180 peroxidation, reacted with Thiobarbituric Acid (TBA) to form an MDA-TBA adduct. The
181 absorbance of the supernatant was measured on a spectrophotometer at $\lambda = 532$ nm. The MDA
182 concentration was calculated using the regression equation of the standard MDA (standard)
183 solution curve.

184 **Statistical Analysis**

185 Statistical Package for Social Scientists (SPSS Inc., USA) version 25.0 software was used for
186 statistical analyses, including descriptive statistics. Continuous data were presented as mean \pm
187 standard error of mean (SEM), whereas categorical data were expressed as a frequency and
188 percentage. The Kolmogorov Smirnov test was used to determine the normality of the
189 variables. Parametric variables were compared using one-way analysis of variance (ANOVA),
190 while chi-square or Fisher's exact test was used for categorical variables. The Pearson
191 correlation test was used to examine the relationships between measured parameters. Multiple
192 linear regression analysis was used to determine independent predictors of the regulators of
193 apoptosis and cell cycle (p53 and bcl2 proteins) in the entire study population. All p values less
194 than 0.05 were deemed statistically significant.

195 **Results**

196 **Demographic Characteristics**

197 The demographic characteristics of study participants are presented in Fig 1 and Table 1. The
198 proportions of HIV-positive and HIV-negative participants were comparable when divided into
199 jobs that predispose workers to chemical exposure (Fig 1A) and those that do not (Fig 1B).
200 Age, gender, place of residence, current employment status, and duration of occupation were
201 comparable between HIV positive and HIV negative individuals in the occupationally exposed

202 and unexposed groups (Table 1). The occupationally exposed group in this study had worked
203 across different occupations linked to toxic metals and hazardous chemicals. While BMI was
204 comparable between HIV positive and HIV negative individuals in the occupationally exposed
205 group, HIV positive individuals had a significantly higher BMI than HIV negative individuals
206 in the occupationally exposed group. The participants' ages ranged from 18–65 years, with a
207 mean \pm SE of 38.35 ± 0.72 , and they were found to have worked for an average of 10.57 ± 0.61
208 years. The mean duration of HIV exposure in the HIV positive group was 42.67 ± 2.45 months.

209 **Fig 1. Comparable HIV status in study group: (A) Chemical-exposed job category and**
210 **(B) Unexposed job category**

- 211 A. *HPE (HIV positive exposed) vs HNE (HIV negative exposed)*
212 B. *HPU (HIV positive unexposed) vs HNU (HIV negative unexposed).*
213 $\chi^2 =$ Chisquare

214 **Table 1. Comparison of demographic characteristics of HIV-positive and HIV-negative participants within occupational categories**

Characteristics	Occupationally Exposed				Occupationally Unexposed			
	HIV Positive (n=62)	HIV Negative (n=60)	χ^2	p-value	HIV Positive (n=66)	HIV Negative (n=60)	χ^2	p-value
^{ab} Age (Years)	38.84 ± 1.34	37.80 ± 1.44	0.53	0.60	39.36 ± 1.51	37.27 ± 1.43	1.00	0.32
Gender			0.03	0.88			0.03	0.96
Female, n(%)	11(17.7%)	10(16.7%)			19(28.8%)	17(28.3%)		
Male, n(%)	51(82.3%)	50(83.3%)			47(71.2%)	43(71.7%)		
Place of Residence			0.41	0.52			4.22	0.06
Rural, n(%)	12(19.4%)	9(15%)			7(10.6%)	9(15%)		
Urban, n(%)	50(80.6%)	51(85%)			59(89.4%)	51(85%)		
Current Employment Status			d	d			0.03	0.87
Employed, n(%)	62(100%)	60(100%)			46(69.7%)	41(68.3%)		
Unemployed, n(%)	0(0%)	0(0%)			20(30.3%)	19(31.7%)		
^{ab} Duration on occupation (years)	9.94 ± 1.14	9.73 ± 1.06	0.13	0.90	12.70 ± 1.38	10.37 ± 1.34	1.21	0.23
^{ab} BMI	26.65 ± 0.56	26.12 ± 0.41	0.76	0.45	26.69 ± 0.30	25.62 ± 0.26	2.70	0.01*

215 ^aValues are Mean ± SEM; ^bt statistics; * Statistically significant: p<0.05; χ^2 = Chi-square

216 d = No statistics were computed because 'Current Employment Status' for the occupationally exposed group is a constant.

217 Levels of p53 and other biomarkers

218 The levels of apoptotic regulatory biomarkers wild-type p53 and bcl2, genotoxic biomarkers
 219 8OHdG and MDA, as well as the antioxidant enzyme SOD and the immunological marker
 220 CD4, are presented in Fig 2. The molecular markers p53 and bcl2 decreased in the HPE group
 221 compared to the HPU, HNE, and HNU groups, respectively. While the HPE group had
 222 significantly lower p53 and bcl2 levels than the HNU group ($p = 0.01$ and $p = 0.03$
 223 respectively), comparisons between the HPE group and the other two groups [HPU ($p = 0.99$
 224 and $p = 0.84$ respectively) and HNE ($p = 0.18$ and $p = 0.14$ respectively)] were not significant.
 225 In contrast, the HPE group had higher 8OHdG levels than the HPU and HNE groups, although
 226 the difference was not statistically significant ($p = 0.19$ and $p = 0.44$ respectively).
 227 Additionally, SOD activity decreased in the HPE group relative to the HPU, HNE, and HNU
 228 groups, but the difference was not significant ($p > 0.05$). The MDA levels were significantly
 229 higher in the HPE group than in the HNE or HNU groups, respectively ($p = 0.04$ and $p = 0.01$
 230 respectively). Additionally, the HPE group had higher MDA levels than the HPU group, but
 231 the difference was not significant ($p > 0.05$). Moreover, p53 and bcl2 levels were positively
 232 and significantly correlated with 8OHdG ($r=0.35$, $p<0.001$; $r=0.36$, $p<0.001$), SOD ($r=0.38$,
 233 $p<0.001$; $r=0.39$, $p<0.001$) whereas p53 and bcl2 levels were negatively but not significantly
 234 correlated with MDA ($r=-0.03$, $p=0.67$; $r=-0.05$, $p=0.43$) (Table 2).

235 Fig 2. Comparison of the levels of p53 and other markers across study group

- 236
- 237 ▪ *Overall *p*-value across the study group (ANOVA results)
 - 238 ▪ bcl2 = β -cell lymphoma; 8-OHdG = 8-Hydroxydeoxyguanosine; SOD = Superoxide Dismutase; MDA =
 - 239 Malondialdehyde
 - 240 ▪ Pairwise comparison (Post hoc analysis): Bars with no superscript letter in common differ significantly (p
 - 241 < 0.05). The error bars show the standard error of the mean; values are mean \pm Standard Error.
 - 242 ▪ Study groups: HIV positive exposed (HPE; $n = 62$), HIV positive unexposed (HPU; $n = 66$), HIV negative
 - 243 exposed (HNE; $n = 60$), and HIV negative unexposed (HNU; $n = 60$).
 - 244

245 Table 2. Correlations between the evaluated biomarkers in the study population

	p53	bcl2	MDA	8OHdG	SOD
p53	1				
bcl2	0.91**	1			
MDA	-0.03	-0.05	1		
8OHdG	0.35**	0.36**	0.01	1	
SOD	0.38**	0.39**	-0.07	0.76**	1
CD4	0.11	0.05	-0.14*	0.05	0.03

** . Correlation is significant at the 0.01 level (2-tailed).

* . Correlation is significant at the 0.05 level (2-tailed).

246

247 CD4 cell count - an indicator of immunological function

248 The immunological condition of the occupationally exposed and unexposed research
 249 participants is summarised in Fig 2 and Table 3 using the Centers for Disease Control and
 250 Prevention (CDC) CD4 count classification criteria of 500 cells/L; 200-499 cells/L; and 200

251 cells/L. In the occupationally exposed group, a significantly smaller proportion of HIV positive
 252 participants (54.8%) had CD4 cell counts ≥ 500 cells/ μ L compared with 85% of HIV negative
 253 participants. Similarly, in the occupationally unexposed group, a significantly smaller
 254 proportion of HIV positive participants (50%) had CD4 cell counts ≥ 500 cells/ μ L compared
 255 with 93.3% of HIV negative participants.

256 A bar chart indicating the possible association between two categorical variables, occupational
 257 chemical exposure and CD4 cell count stratified by HIV status, is depicted in Fig 2. There was
 258 no association between occupational exposure and CD4 count categories in the HIV positive
 259 study participants ($\chi^2(2) = 4.43, p = 0.11$) and in the HIV negative individuals ($\chi^2(2) = 2.16,$
 260 $p = 0.14$). However, the occupationally exposed HIV positive group (578.87 ± 33.64 cells/ μ L)
 261 and the HIV positive unexposed group (553.95 ± 36.86 cells/ μ L) had significantly lower CD4
 262 counts than the HIV negative exposed (785.35 ± 36.8 cells/ μ L) and HIV negative unexposed
 263 (862.15 ± 43.29 cells/ μ L) groups (Fig 2). CD4 cell count was negatively and significantly
 264 correlated with MDA ($r = -0.14, p = 0.03$) (Table 2).

265 **Table 3. Immunological Status of Study Groups**

^aImmune Status	HIV Positive	HIV Negative	Test statistics	p-value
Occupationally Exposed			^b 13.35	<0.001
CD4 Count ≥ 500 cells/ μ L	34(54.8%)	51(85%)		
CD4 Count 200-499 cells/ μ L	26(41.9%)	9(15%)		
CD4 Count <200 cells/ μ L	2(3.2%)	0(0%)		
Total n(%)	62(100%)	60(100%)		
Occupationally Unexposed			^b 30.67	<0.001
CD4 Count ≥ 500 cells/ μ L	33(50%)	56(93.3%)		
CD4 Count 200-499 cells/ μ L	24(36.4%)	4(6.7%)		
CD4 Count <200 cells/ μ L	9(13.6%)	0(0%)		
Total n(%)	66(100%)	60(100%)		

266 ^aClassification based on 2014 CDC Case Definition for HIV Infection Among Adolescents and
 267 Adults [37].

268 ^bFisher's Exact Test Value

269

270 **Multiple linear regression for indicators of genotoxicity and** 271 **apoptosis regulation**

272 To examine the relationship between indicators of genotoxicity and apoptosis regulation using
 273 multiple linear regression, occupational chemical exposure, HIV status, CD4, SOD, 8OHdG,
 274 and MDA were used as predictor variables, while apoptosis regulation markers, p53 and bcl2
 275 were used as dependent variables. After adjusting for sex, age, BMI, and cigarette smoking,
 276 both HIV status and SOD activity were significantly associated with wildtype p53 and bcl2 (p
 277 < 0.05) (Table 4).

278

279 **Table 4. Effect of occupational exposure, HIV status and other biomarkers on p53 and**
280 **bcl2**

	B	SE	Beta	t	sig.	Adjusted R ²	^a p-value
p53						0.17	<0.001*
Exposure	94.30	118.91	0.05	0.79	0.43		
HIV status	369.87	131.28	0.19	2.82	0.01*		
CD4	0.09	0.20	0.03	0.48	0.63		
SOD	9.48	3.05	0.29	3.11	0.00*		
8OHdG	51.92	47.32	0.10	1.10	0.27		
MDA	608.31	828.96	0.04	0.73	0.46		
bcl2						0.18	<0.001*
Exposure	22.48	22.92	0.06	0.98	0.33		
HIV status	69.00	25.31	0.18	2.73	0.01*		
CD4	-0.03	0.04	-0.05	-0.72	0.47		
SOD	1.63	0.59	0.25	2.77	0.01*		
8OHdG	15.61	9.12	0.16	1.71	0.09		
MDA	15.55	159.79	0.01	0.10	0.92		

281 Dependent Variables: p53 and bcl2

282 Predictors: Occupational chemical exposure, HIV status, CD4, SOD, 8OHdG, MDA

283 B = Unstandardized Coefficients; Beta = Standardized Coefficients; ^aRegression model p-value

284 * Statistically significant at p < 0.05

285

286 **DISCUSSION:**

287 The co-occurrence of HIV infection and occupational exposure to hazardous chemicals poses
288 a major concern in public health, as both factors may facilitate the concurrent degradation of
289 both immunological and non-immune surveillance mechanisms against cancer. This study
290 investigated the complex association between apoptotic regulatory markers and DNA oxidative
291 response markers in the context of cancer susceptibility among individuals infected with HIV,
292 who were also exposed to a cocktail of hazardous substances, including metals. The findings
293 of this study indicate that p53 and bcl2 levels, which control apoptosis, were associated with
294 HIV infection, oxidative damage, and a tendency for antioxidant depletion. Additionally, the
295 decrease in wildtype p53 and bcl2 levels, as well as the increase in malondialdehyde levels,
296 among HIV-positive individuals who had occupational exposure to chemical mixtures provides
297 insight into the potential role of oxidative stress in viral and chemical carcinogenesis.

298 Individuals who were HIV-positive and had been exposed to chemical mixtures at work
299 demonstrated notably reduced levels of p53 and bcl2 in comparison to HIV-negative persons
300 who had not been exposed. This observation implies a plausible association between the co-
301 occurrence of HIV infection and exposure to occupational chemicals, and a disruption in the
302 apoptotic pathways. The proteins p53 and bcl2 are crucial in maintaining the equilibrium
303 between cell survival and cell death [39]. Hence, the observed decrease in p53 and bcl2 levels
304 could indicate an imbalance between cell proliferation and apoptosis in individuals infected by
305 HIV and exposed to hazardous chemical agents, suggestive of a potential predisposition to
306 malignancy. In a study that shares some similarities, Gruevska *et al.* [40] found that HIV
307 patients had significantly lower levels of the tumour suppressor gene p53 than uninfected
308 matched individuals, and that this decreased expression of p53 was also observed at the protein
309 level.

310 Malondialdehyde functions as a reliable marker for assessing lipid peroxidation and oxidative
311 damage. In this study, occupationally exposed HIV positive individuals had increased MDA
312 levels, indicating that individuals infected with HIV and exposed to occupational chemicals
313 experience elevated levels of oxidative stress. This finding is consistent with the literature
314 suggesting that exposure to certain chemicals in the workplace, such as toxic metals, may cause
315 oxidative stress, leading to further damage to cellular constituents, including DNA [41,42].
316 Indeed, the presence of HIV infection may create an enabling environment favourable for
317 cancer development, owing to immune suppression as well as processes such as DNA
318 mutations and defective DNA repair, which can be attributed to mitochondrial dysfunction and
319 elevated oxidative stress [43].

320 Oxidative stress in occupationally exposed HIV-infected individuals, may contribute to the
321 impairment of p53 function, potentially leading to the initiation or progression of
322 carcinogenesis. Although p53 is generally activated in response to DNA damage, chronic
323 exposure to occupational carcinogens may result in prolonged activation and ultimately
324 depletion of p53. Therefore, the decreased wildtype p53 in response to chronic occupational
325 chemical exposure and HIV infection observed in this study may compromise the critical role
326 of p53 in preserving DNA integrity and preventing cancer. This agrees with studies
327 demonstrating that people living with HIV or exposed to chemical carcinogens showed
328 increased genomic instability [16,44]. Oxidative stress plays a critical role in chemical and
329 viral carcinogenesis [45,46].

330 Multiple factors could potentially influence the susceptibility of cells to cancer. The observed
331 association between HIV status, 8OHdG and SOD, with levels of wildtype p53 and bcl2
332 suggest that these indicators are influenced not only by individual exposures but also by the
333 combined factors altering cellular responses to oxidative stress and apoptosis. The complex
334 relationship between these factors highlights the diverse and intricate mechanisms that
335 contribute to the risk of cancer in people living with HIV but also exposed to chemical toxins.
336 This observation is consistent with previous studies that proposed a relationship between HIV
337 infection and oxidative stress, which can result in changes to cellular mechanisms, such as
338 apoptotic pathways [43,47]. Darbinian *et al.* [48] demonstrated the initiation of apoptotic
339 responses following elevated mtDNA damage in cells treated with HIV-1 proteins or infected
340 with HIV-1. Conversely, the accumulation of damaged DNA can result from abnormal or
341 failure of apoptosis which may lead to cancer [49].

342 A decreased CD4 cell count was observed in HIV-infected individuals regardless of
343 occupational chemical exposure. This aligns with the prevailing consensus that HIV infection
344 impairs the immune system by preferentially destroying CD4-positive T cells. Indeed, the
345 altered immunological profiles of the HIV-positive study population are consistent with
346 previous research on the detrimental effect of HIV infection on immune system functionality
347 [50,51]. Moreover, the observation of a negative correlation between CD4 count and MDA
348 concentrations provides further evidence for the probable influence of both HIV infection and
349 chemical exposures on cellular pathways associated with oxidative stress and apoptosis. Our
350 findings suggest that impaired immune surveillance indicated by low CD4 cell count may
351 impede the body's capacity to identify and eradicate malignant or pre-malignant cells, therefore
352 play a role in increased cancer risk among HIV-infected workers. Furthermore, these findings
353 are consistent with evidence indicating that oxidative stress plays a pivotal role in the
354 interconnection between viral infections, hazardous exposures, and the development of cancer
355 [52–54]. This may potentially interact with chemical exposures, leading to an increased
356 vulnerability to cancer. Kang *et al.* [55] demonstrated that an intact CD4(+) T-cell-mediated
357 adaptive immune response is important for tumour immune surveillance.

358 The present study highlights the complex relationships among apoptotic regulatory indicators,
359 DNA oxidative response markers, and the risk of cancer in a distinct population of HIV-
360 infected individuals who have been occupationally exposed to hazardous chemicals. Notably,
361 the current study underscored the influence of both HIV infection and chemical exposures on
362 cellular pathways associated with oxidative stress and apoptosis. The majority of prior studies
363 focused on the influence of HIV infection or occupational exposure on oxidative stress
364 indicators in isolation [54,56]. However, it is imperative to acknowledge the study's limitations.
365 The cross-sectional design makes it difficult to establish causal relationships between
366 occupational chemical exposure, HIV infection, and changes in levels of cancer risk
367 biomarkers studied. Secondly, the study did not investigate specific cancer types or long-term
368 cancer outcomes, which could have provided valuable insight into the clinical implications of
369 these findings. Longitudinal studies are advocated to provide more robust evidence.

370 **Conclusion**

371 Immune deficiency, antioxidant deficits, oxidative stress, and dysregulation of apoptosis
372 contribute to increased genomic instability and elevated cancer risk in HIV infected individuals
373 occupationally exposed to chemical mixtures. In addition, our findings suggest that optimal
374 levels of the enzymatic antioxidant SOD may be essential for p53 to play its protective role in
375 maintaining genomic stability. These findings highlight the need of designing and
376 implementing preventive interventions to reduce the risk of viral and chemical carcinogenesis
377 among the vulnerable population of HIV-infected individuals exposed to occupational
378 chemical hazards.

379 **Acknowledgements**

380 The authors extend their gratitude to the study's community outreach team, led by Mr. Saviour
381 Nkanu, for their support in participant recruitment and to all participants involved in this study.

382

383 **Author Contributions**

384 Conceptualization: Donald C. UDAH, Adeleye S. Bakarey, Olusegun G. Ademowo, John I.
385 Anetor

386 Data curation: Donald C. UDAH, Adeleye S. Bakarey, Maxwell Omabe, Victory F. Edem

387 Formal analysis: Donald C. UDAH, Gloria O. Anetor, Olusegun G. Ademowo, John I. Anetor

388 Funding acquisition: Donald C. UDAH, John I. Anetor

389 Investigation: Donald C. UDAH, Adeleye S. Bakarey, Gloria O. Anetor, Victory F. Edem,
390 Olusegun G. Ademowo, John I. Anetor

391 Methodology: Donald C. UDAH, Adeleye S. Bakarey, Gloria O. Anetor, Maxwell Omabe,
392 Victory F. Edem

393 Supervision: Olusegun G. Ademowo, John I. Anetor

394 Visualization: Donald C. UDAH, Maxwell Omabe

395 Writing – original draft: Donald C. UDAH

396 Writing – review & editing: Donald C. UDAH, Adeleye S. Bakarey, Gloria O. Anetor, Maxwell
397 Omabe, Victory F. Edem, Olusegun G. Ademowo, John I. Anetor

398 **References**

399 1. Engels EA, Pfeiffer RM, Fraumeni JFJ, Kasiske BL, Israni AK, Snyder JJ, et al.
400 Spectrum of cancer risk among US solid organ transplant recipients. *JAMA*. 2011;306:
401 1891–1901. doi:10.1001/jama.2011.1592

402 2. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in
403 people with HIV/AIDS compared with immunosuppressed transplant recipients: a
404 meta-analysis. *Lancet (London, England)*. 2007;370: 59–67. doi:10.1016/S0140-
405 6736(07)61050-2

406 3. Schwartz RS. Immunodeficiency, immunosuppression, and susceptibility to
407 neoplasms. *J Natl Cancer Inst Monogr*. 2001; 5–9.
408 doi:10.1093/oxfordjournals.jncimonographs.a024257

409 4. Castelli R, Schiavon R, Preti C, Ferraris L. Hiv-Related Lymphoproliferative
410 Diseases In The Era Of Combination Antiretroviral Therapy. *Cardiovascular &*
411 *hematological disorders drug targets*. United Arab Emirates; 2020.
412 doi:10.2174/1871529X20666200415121009

413 5. Odutola M, Jedy-Agba EE, Dareng EO, Oga EA, Igbinoba F, Otu T, et al. Burden of
414 Cancers Attributable to Infectious Agents in Nigeria: 2012-2014. *Front Oncol*. 2016;6:
415 216. doi:10.3389/fonc.2016.00216

416 6. Zucchetto A, Virdone S, Tadorelli M, Grande E, Camoni L, Pappagallo M, et al. Non-
417 AIDS-Defining Cancer Mortality: Emerging Patterns in the Late HAART Era. *J*
418 *Acquir Immune Defic Syndr*. 2016;73: 190–196. doi:10.1097/QAI.0000000000001033

419 7. Franzetti M, Ricci E, Bonfanti P. The Pattern of Non-AIDS-defining Cancers in the
420 HIV Population: Epidemiology, Risk Factors and Prognosis. A Review. *Curr HIV*
421 *Res*. 2019;17: 1–12. doi:10.2174/1570162X17666190327153038


- 422 8. Hemann MT, Lowe SW. The p53-bcl-2 connection. *Cell Death Differ*. 2006;13: 1256.
- 423 9. Omotosho IO. Oxidative stress indices as markers of lead and cadmium exposure
424 toxicity in auto technicians in Ibadan, Nigeria. *Oxid Med Cell Longev*. 2019;2019.
- 425 10. Guth K, Bourgeois M, Johnson G, Harbison R. Assessment of lead exposure controls
426 on bridge painting projects using worker blood lead levels. *Regul Toxicol Pharmacol*.
427 2020;115: 104698. doi:10.1016/j.yrtph.2020.104698
- 428 11. Peters CE, Parent M-É, Harris SA, Bogaert L, Latifovic L, Kachuri L, et al.
429 Occupational Exposure to Diesel and Gasoline Engine Exhausts and the Risk of
430 Kidney Cancer in Canadian Men. *Ann Work Expo Heal*. 2018;62: 978–989.
431 doi:10.1093/annweh/wxy059
- 432 12. Torén K, Blanc PD, Naidoo RN, Murgia N, Qvarfordt I, Aspevall O, et al.
433 Occupational exposure to dust and to fumes, work as a welder and invasive
434 pneumococcal disease risk. *Occup Environ Med*. 2020;77: 57–63. doi:10.1136/oemed-
435 2019-106175
- 436 13. Poirier MC. Linking DNA adduct formation and human cancer risk in chemical
437 carcinogenesis. *Environ Mol Mutagen*. 2016;57: 499–507. doi:10.1002/em.22030
- 438 14. Anetor, J.I., Udah, D., Akingbola, T. S., Anetor, G. O., Babalola, O., Igharo, O.G.,
439 Uche, Z. C., & Adeniyi FAA. Upregulation of gamma-glutamyltranspeptidase activity
440 and uric acid level in mixed chemical exposure: Implications for mutagenic and pre-
441 neoplastic events. *Int J Biol Chem Sci*. 2016;10: 2655–2666.
- 442 15. International Agency for Research on Cancer (IARC). Chemical agents and related
443 occupations. *IARC Monogr Eval Carcinog risks to humans*. 2012;100: 9–562.
- 444 16. Kovalchuk O. Chemical carcinogens and their effect on genome and epigenome
445 stability. *Genome Stability*. Elsevier; 2021. pp. 589–602.
- 446 17. Barsouk A, Thandra KC, Saginala K, Rawla P, Barsouk A. Chemical Risk Factors of
447 Primary Liver Cancer: An Update. *Hepat Med*. 2020;12: 179–188.
448 doi:10.2147/HMER.S278070
- 449 18. Hatano Y, Ideta T, Hirata A, Hatano K, Tomita H, Okada H, et al. Virus-Driven
450 Carcinogenesis. *Cancers (Basel)*. 2021;13. doi:10.3390/cancers13112625
- 451 19. Klein G, Klein E. Surveillance against tumors—is it mainly immunological? *Immunol*
452 *Lett*. 2005;100: 29–33.
- 453 20. Okorokov AL, Orlova E V. Structural biology of the p53 tumour suppressor. *Curr*
454 *Opin Struct Biol*. 2009;19: 197–202. doi:10.1016/j.sbi.2009.02.003
- 455 21. Park J-H, Zhuang J, Li J, Hwang PM. p53 as guardian of the mitochondrial genome.
456 *FEBS Lett*. 2016;590: 924–934. doi:10.1002/1873-3468.12061
- 457 22. Stewart-Ornstein J, Lahav G. p53 dynamics in response to DNA damage vary across
458 cell lines and are shaped by efficiency of DNA repair and activity of the kinase ATM.
459 *Sci Signal*. 2017;10. doi:10.1126/scisignal.aah6671
- 460 23. Pellegata NS, Antoniono RJ, Redpath JL, Stanbridge EJ. DNA damage and p53-
461 mediated cell cycle arrest: a reevaluation. *Proc Natl Acad Sci*. 1996;93: 15209–15214.
- 462 24. Leroy B, Anderson M, Soussi T. TP53 mutations in human cancer: database

- 463 reassessment and prospects for the next decade. *Hum Mutat.* 2014;35: 672–688.
464 doi:10.1002/humu.22552
- 465 25. Obaji-Ogar LT, Nsonwu-Anyanwu AC, Odum FA. Oxidative DNA Damage and Pro-
466 inflammatory Response In Chronic Exposure To Cement Dust. *Asia Pacific J Med*
467 *Toxicol.* 2020;9: 3–10.
- 468 26. Ogunbileje JO, Sadagoparamanujam V-M, Anetor JI, Farombi EO, Akinosun OM,
469 Okorodudu AO. Lead, mercury, cadmium, chromium, nickel, copper, zinc, calcium,
470 iron, manganese and chromium (VI) levels in Nigeria and United States of America
471 cement dust. *Chemosphere.* 2013;90: 2743–2749.
- 472 27. Igharo OG, Anetor JI, Osibanjo O, Okungbowa MA, Aleoghena TO, Idomeh FA, et al.
473 Variation in Some Haematological Parameters, Iron and Lead Levels in Workers
474 Exposed to Electronic Waste in Benin City, South-South Nigeria. *J Med Lab Sci.*
475 2020;30: 50–58.
- 476 28. Ward MS, Henderson AM, Rossi E, Raven JL. Lead poisoning in an electrician: a bad
477 substitute for a bad habit. *Med J Aust.* 1997;166: 23–24. doi:10.5694/j.1326-
478 5377.1997.tb138697.x
- 479 29. Wortley PM, Caraballo RS, Pederson LL, Pechacek TF. Exposure to secondhand
480 smoke in the workplace: serum cotinine by occupation. *J Occup Environ Med.*
481 2002;44: 503–509. doi:10.1097/00043764-200206000-00010
- 482 30. Semple S, Maccalman L, Naji AA, Dempsey S, Hilton S, Miller BG, et al. Bar
483 workers' exposure to second-hand smoke: the effect of Scottish smoke-free legislation
484 on occupational exposure. *Ann Occup Hyg.* 2007;51: 571–580.
485 doi:10.1093/annhyg/mem044
- 486 31. Rabczyński M, Kuźnik E, Guziński M, Adamiec R. Critical ischemia of the fingers in
487 an auto mechanic as a result of occupational exposure. *Int J Occup Med Environ*
488 *Health.* 2015;28: 169–173. doi:10.2478/s13382-014-0293-5
- 489 32. Moura LTR de, Bedor CNG, Lopez RVM, Santana VS, Rocha TMB da S da, Wunsch
490 Filho V, et al. Occupational exposure to organophosphate pesticides and hematologic
491 neoplasms: a systematic review. *Rev Bras Epidemiol.* 2020;23: e200022.
492 doi:10.1590/1980-549720200022
- 493 33. Buralli RJ, Ribeiro H, Iglesias V, Muñoz-Quezada MT, Leão RS, Marques RC, et al.
494 Occupational exposure to pesticides and health symptoms among family farmers in
495 Brazil. *Rev Saude Publica.* 2020;54: 133. doi:10.11606/s1518-8787.2020054002263
- 496 34. Ghittori S, Ferrari M, Maestri L, Negri S, Zadra P, Gremita C, et al. [The significance
497 of enviromental and biological monitoring in workers employed in service stations
498 after the elimitation of tetraethyl lead from gasoline]. *G Ital Med Lav Ergon.* 2005;27:
499 137–153.
- 500 35. Patel HK, Ikpe S, Bronson M, Birhanu S, Abimiku A, Jahun I, et al. Performance of
501 HIV rapid testing algorithm in Nigeria: Findings from a household-based Nigeria
502 HIV/AIDS Indicator and Impact Survey (NAIIS). *PLOS Glob Public Heal.* 2022;2:
503 e0000466.
- 504 36. Pattanapanyasat K, Sukapirom K, Kowawisatsut L, Thepthai C. New BD FACSCount
505 CD4 reagent system for simultaneous enumeration of percent and absolute CD4 T-

- 506 lymphocytes in HIV-1-infected pediatric patients. *Cytometry B Clin Cytom.* 2008;74
507 Suppl 1: S98-106. doi:10.1002/cyto.b.20415
- 508 37. CDC. Revised surveillance case definition for HIV infection--United States, 2014.
509 *MMWR Recomm reports Morb Mortal Wkly report Recomm reports.* 2014;63: 1–10.
- 510 38. Buege JA, Aust SD. Microsomal lipid peroxidation. *Methods Enzymol.* 1978;52: 302–
511 310. doi:10.1016/s0076-6879(78)52032-6
- 512 39. Ayed D Ben, Khabir A, Abid M, Bayrouiti MI, Gargouri A, Sellami-Boudawara T, et
513 al. Clinicopathological and prognostic significance of p53, Ki-67, and Bel-2
514 expression in Tunisian gastric adenocarcinomas. *Acta Histochem.* 2014;116: 1244–
515 1250. doi:10.1016/j.acthis.2014.07.008
- 516 40. Gruevska A, Moragrega AB, Galindo MJ, Esplugues J V, Blas-Garcia A, Apostolova
517 N. p53 and p53-related mediators PAI-1 and IGFBP-3 are downregulated in peripheral
518 blood mononuclear cells of HIV-patients exposed to non-nucleoside reverse
519 transcriptase inhibitors. *Antiviral Res.* 2020;178: 104784.
520 doi:10.1016/j.antiviral.2020.104784
- 521 41. Fu Z, Xi S. The effects of heavy metals on human metabolism. *Toxicol Mech*
522 *Methods.* 2020;30: 167–176. doi:10.1080/15376516.2019.1701594
- 523 42. Gueguen Y, Bontemps A, Ebrahimian TG. Adaptive responses to low doses of
524 radiation or chemicals: their cellular and molecular mechanisms. *Cell Mol Life Sci.*
525 2018. doi:10.1007/s00018-018-2987-5
- 526 43. Schank M, Zhao J, Moorman JP, Yao ZQ. The Impact of HIV- and ART-Induced
527 Mitochondrial Dysfunction in Cellular Senescence and Aging. *Cells.* 2021;10.
528 doi:10.3390/cells10010174
- 529 44. Gutiérrez-Sevilla JE, Cárdenas-Bedoya J, Escoto-Delgadillo M, Zúñiga-González GM,
530 Pérez-Ríos AM, Gómez-Meda BC, et al. Genomic instability in people living with
531 HIV. *Mutat Res Genet Toxicol Environ Mutagen.* 2021;865: 503336.
532 doi:10.1016/j.mrgentox.2021.503336
- 533 45. Isagulants M, Bayurova E, Avdoshina D, Kondrashova A, Chiodi F, Palefsky JM.
534 Oncogenic Effects of HIV-1 Proteins, Mechanisms Behind. *Cancers (Basel).* 2021;13.
535 doi:10.3390/cancers13020305
- 536 46. Klaunig JE, Wang Z, Pu X, Zhou S. Oxidative stress and oxidative damage in
537 chemical carcinogenesis. *Toxicol Appl Pharmacol.* 2011;254: 86–99.
538 doi:10.1016/j.taap.2009.11.028
- 539 47. Lagathu C, Cossarizza A, Béréziat V, Nasi M, Capeau J, Pinti M. Basic science and
540 pathogenesis of ageing with HIV: potential mechanisms and biomarkers. *AIDS.*
541 2017;31 Suppl 2: S105–S119. doi:10.1097/QAD.0000000000001441
- 542 48. Darbinian N, Darbinyan A, Merabova N, Selzer ME, Amini S. HIV-1 and HIV-1-Tat
543 Induce Mitochondrial DNA Damage in Human Neurons. *J HIV AIDS.* 2020;6.
544 doi:10.16966/2380-5536.176
- 545 49. D'arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and
546 autophagy. *Cell Biol Int.* 2019;43: 582–592.
- 547 50. de Goede AL, Vulto AG, Osterhaus ADME, Gruters RA. Understanding HIV infection

- 548 for the design of a therapeutic vaccine. Part I: Epidemiology and pathogenesis of HIV
549 infection. *Ann Pharm Fr.* 2015;73: 87–99. doi:10.1016/j.pharma.2014.11.002
- 550 51. Fernández-Ruiz A, Sanjoaquin-Conde I, Letona-Carbajo S, Lambea-Sorrosal JJ,
551 Crusells-Canales MJ. Differences in survival according to malignancy type and degree
552 of immunodeficiency in HIV-infected patients. *Med Clin (Barc).* 2020;154: 295–300.
553 doi:10.1016/j.medcli.2019.06.019
- 554 52. Kumar N, Kumari V, Ram C, Kumar BSB, Verma S. Impact of oral cadmium
555 intoxication on levels of different essential trace elements and oxidative stress
556 measures in mice: a response to dose. *Environ Sci Pollut Res.* 2018;25: 5401–5411.
- 557 53. Adeyanju K, Bend JR, Rieder MJ, Dekaban GA. HIV-1 tat expression and
558 sulphamethoxazole hydroxylamine mediated oxidative stress alter the disulfide
559 proteome in Jurkat T cells. *Virology.* 2018;15: 82. doi:10.1186/s12985-018-0991-x
- 560 54. Anlar HG, Bacanlı M, İritaş S, Bal C, Kurt T, Tutkun E, et al. Effects of Occupational
561 Silica Exposure on OXIDATIVE Stress and Immune System Parameters in Ceramic
562 Workers in TURKEY. *J Toxicol Environ Health A.* 2017;80: 688–696.
563 doi:10.1080/15287394.2017.1286923
- 564 55. Kang T-W, Yeysa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, et al. Senescence
565 surveillance of pre-malignant hepatocytes limits liver cancer development. *Nature.*
566 2011;479: 547–551. doi:10.1038/nature10599
- 567 56. Mebrat Y, Amogne W, Mekasha A, Gleason RLJ, Seifu D. Lipid Peroxidation and
568 Altered Antioxidant Profiles with Pediatric HIV Infection and Antiretroviral Therapy
569 in Addis Ababa, Ethiopia. *J Trop Pediatr.* 2017;63: 196–202.
570 doi:10.1093/tropej/fmw076
- 571

A



B




Figure 1









Figure 2